BioNTech (NASDAQ:BNTX) Receives Buy Rating from Jefferies Financial Group

BioNTech (NASDAQ:BNTX)‘s stock had its “buy” rating restated by Jefferies Financial Group in a report released on Wednesday,MarketScreener reports.

A number of other analysts have also recently issued reports on the company. Leerink Partners cut BioNTech from an “outperform” rating to a “market perform” rating and set a $113.00 target price for the company. in a research report on Monday, February 2nd. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of BioNTech in a report on Tuesday, March 17th. Citigroup lowered their target price on shares of BioNTech from $145.00 to $130.00 and set a “buy” rating on the stock in a research report on Wednesday, March 11th. TD Cowen cut their target price on shares of BioNTech from $116.00 to $94.00 and set a “hold” rating on the stock in a report on Wednesday, March 11th. Finally, Truist Financial set a $155.00 price target on shares of BioNTech in a research report on Tuesday, March 10th. Thirteen analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $133.73.

BioNTech Trading Up 2.1%

NASDAQ BNTX opened at $88.64 on Wednesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.54 and a quick ratio of 7.49. BioNTech has a 12 month low of $79.52 and a 12 month high of $124.00. The company has a market capitalization of $21.27 billion, a price-to-earnings ratio of -16.93 and a beta of 1.51. The firm’s fifty day moving average price is $104.95 and its 200 day moving average price is $101.91.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Rhenman & Partners Asset Management AB grew its position in BioNTech by 0.3% in the 2nd quarter. Rhenman & Partners Asset Management AB now owns 35,870 shares of the company’s stock valued at $3,819,000 after buying an additional 120 shares during the last quarter. Kennedy Capital Management LLC increased its stake in BioNTech by 0.8% in the 2nd quarter. Kennedy Capital Management LLC now owns 16,422 shares of the company’s stock valued at $1,748,000 after buying an additional 127 shares during the period. Larson Financial Group LLC lifted its stake in shares of BioNTech by 86.4% in the 4th quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock worth $26,000 after acquiring an additional 127 shares during the period. Probity Advisors Inc. lifted its stake in shares of BioNTech by 5.7% in the 3rd quarter. Probity Advisors Inc. now owns 2,506 shares of the company’s stock worth $247,000 after acquiring an additional 135 shares during the period. Finally, Mackenzie Financial Corp boosted its holdings in shares of BioNTech by 4.0% in the third quarter. Mackenzie Financial Corp now owns 4,290 shares of the company’s stock valued at $418,000 after acquiring an additional 165 shares in the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.